Year : 2021 | Volume
: 22 | Issue : 3 | Page : 165--173
The effect of ivabradine on hospitalization of heart failure patients: A retrospective cohort study
Sara Al-Balushi1, Mohammed Fasihul Alam2, Abdul Rehman Abid1, Amal Sharfi1
1 Department of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar
2 Department of Public Health, College of Health Sciences, Health Cluster, Qatar University, Doha, Qatar
Background: Ivabradine is recommended in heart failure (HF) patients to reduce cardiovascular death and hospitalization due to worsening of HF symptoms.
Aims and Objectives: To study the effect of Ivabradine in addition to guideline-directed medical therapy (GDMT) in a group of HF patients with HR more than 70 bpm, HF with reduced ejection fraction (HFrEF) left ventricular ejection fraction (LVEF ≤ 40%), and New York Heart Association class II-IV.
Methods: The study was conducted at Heart Hospital, Hamad Medical Corporation, Qatar. HF patients with age > 18 years, LVEF ≤40%, on GDMT, and HR of ≥70 bpm were included. The study population was divided into two groups: ivabradine group and non-ivabradine group. The primary outcomes were risk, number and length of hospitalizations due to worsening HF, and cardiovascular mortality. The secondary outcome was all-cause mortality. Baseline characteristics were collected at enrollment. Study outcomes were compared in the two groups by applying Chi-square and Fisher's exact tests. Logistic regression model was applied to assess both hospitalizations and cardiovascular mortality.
Results: A total of 111 patients were studied, 37 (33.94%) ivabradine group and 74 (66.67%) non-ivabradine group. Risk of hospitalization was lower in Ivabradine group compared to non-Ivabradine group (odds ratio: 0.43, 95% confidence interval [CI]: 0.16–1.015, P = 0.094). Average length of hospitalization in ivabradine and non-ivabradine groups was 12.54 and 8.91 days, respectively (incidence rate ratio [IRR]: 1.63, 95% CI: 0.79–3.38, P = 0.187). Compared to non-ivabradine, ivabradine patients had lower number of hospitalizations (IRR: 1.13, 95% CI: 0.61–2.11, P = 0.694). Death rate in both ivabradine and non-ivabradine groups was 3.
Conclusions: Ivabradine along with GDMT reduces the risk of hospitalization due to worsening HF symptoms. Ivabradine had no significant effect on cardiovascular mortality and all-cause mortality. HFrEF non-Arabs patients have lower risk, number and length of hospitalization, and mortality compared to Arabs.
Ms. Sara Al-Balushi
Pharmacy Department, Heart Hospital, Hamad Medical Corporation, P.O. BOX 3050, Doha
|How to cite this article:|
Al-Balushi S, Alam MF, Abid AR, Sharfi A. The effect of ivabradine on hospitalization of heart failure patients: A retrospective cohort study.Heart Views 2021;22:165-173
|How to cite this URL:|
Al-Balushi S, Alam MF, Abid AR, Sharfi A. The effect of ivabradine on hospitalization of heart failure patients: A retrospective cohort study. Heart Views [serial online] 2021 [cited 2022 Jul 3 ];22:165-173
Available from: https://www.heartviews.org/article.asp?issn=1995-705X;year=2021;volume=22;issue=3;spage=165;epage=173;aulast=Al-Balushi;type=0